Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364839 | 1.00 | CYP46A1 (0.56) | CYP46A1NR4A2TDP1MEN1KMT2A | |
| SCHEMBL1206018 | 0.85 | CYP46A1 (0.57) | CYP46A1NR4A2TDP1MAPTHPGD | |
| SCHEMBL2126690 | 0.85 | MEN1 (0.52) | CYP46A1NR4A2MEN1KMT2AMAPT | |
| SCHEMBL6113275 | 0.85 | MEN1 (0.52) | CYP46A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL31186730 | 0.85 | MEN1 (0.52) | CYP46A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL7666837 | 0.85 | ALDH1A1 (0.50) | CYP46A1NR4A2TDP1KMT2AMAPT | |
| SCHEMBL70184 | 0.83 | KDM4E (0.47) | CYP46A1NR4A2TDP1MAPTHPGD | |
| SCHEMBL158111 | 0.83 | TDP1 (0.57) | CYP46A1NR4A2TDP1MEN1KMT2A | |
| SCHEMBL20484462 | 0.82 | MEN1 (0.49) | CYP46A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL6893999 | 0.82 | MEN1 (0.49) | CYP46A1MEN1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4185858-B1 | COMPOSITIONS, SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS USING DYES | LIFE TECHNOLOGIES CORP (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250114436-A1 | DYNAMIC-COVALENT HYDROGELS WITH GLUCOSE-SPECIFIC AND GLUCOSE-RESPONSIVE DIBORONATE CROSSLINKING | UNIVERSITY OF NOTRE DAME DU LAC | 2025-04-10 | — | — | US | disclosed |
| EP-4452322-A2 | DYNAMIC-COVALENT HYDROGELS WITH GLUCOSE-SPECIFIC AND GLUCOSE-RESPONSIVE DIBORONATE CROSSLINKING | University of Notre Dame du Lac (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117881668-A | Compound based on isoindoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240060117-A1 | ENERGY TRANSFER DYE CONJUGATES FOR USE IN BIOLOGICAL ASSAYS | Life Technologies Corporation | 2024-02-22 | — | — | US | disclosed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-RE36617-E | Anastrozole and salts as anticancer agent | ZENECA LIMITED (GB) | 2000-03-14 | — | — | US | disclosed |
| EP-0507013-B1 | Process for the preparation of aromatic beta-diketones | WITCO CORP (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0507013-A1 | Process for the preparation of aromatic beta-diketones | WITCO CORPORATION (US) | 1992-10-07 | — | — | EP | disclosed |
| US-5015777-A | Reaction of an acetophenone and an aliphatic ester or an ester of benzoic acid in the presence of sodium alkoxide condensation agent in an aromatic solvent | WITCO CORPORATION (US) | 1991-05-14 | — | — | US | disclosed |
| US-4935437-A | (Substituted aralkyl) heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-19 | — | — | US | disclosed |
| EP-0296749-A1 | (Substituted aralkyl) heterocyclic compounds | ZENECA LIMITED (GB) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | CYP46A1 3116/4885NR4A2 826/4885TDP1 1633/4885 |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | CYP46A1 934/4885NR4A2 1402/4885TDP1 3831/4885 |
| US-20250114436-A1 | DYNAMIC-COVALENT HYDROGELS WITH GLUCOSE-SPECIFIC AND GLUCOSE-RESPONSIVE DIBORONATE CROSSLINKING | IAPP, INSR, GPR119 | CYP46A1 3335/4885NR4A2 1928/4885TDP1 3832/4885 |
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | CYP46A1 1849/4885NR4A2 4277/4885TDP1 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.